We’re Making History!
Received final 510(k) clearance for Integrity™ Implant System, a regenerative hyaluronic acid-based patch system for augmentation of rotator cuff repairs
Completed enrollment in Hyalofast® pivotal Phase III clinical study, a key milestone in its path to achieving US FDA approval
Tactoset® received additional FDA 510(k) clearance to be combined with autogenous bone marrow aspirate (BMA)
First surgeries were performed using the new RevoMotion™ Reverse Shoulder Arthroplasty System and limited market release was initiated
Commenced full market release of X-Twist™ Fixation System, a cornerstone product in Anika’s Sports Medicine portfolio
FDA 510(k) clearance received and first surgeries performed with the X-Twist Fixation System, a highly versatile suture anchor system, and a cornerstone product for Anika’s sports medicine portfolio.
Received the ACE Award for cutting-edge innovation from the American Orthopedic Society for Sports Medicine (AOSSM) for Tactoset® Injectable Bone Substitute for hardware augmentation.
First surgeries were performed using the X-Twist Fixation System and limited market release commenced
Cingal® successfully achieved its primary endpoint in its third Phase III clinical trial
WristMotion® Total Wrist Arthroplasty System launched for the replacement of painful wrist joints.
FDA 510(k) clearance received for Tactoset Injectable Bone Substitute to include a new indication for augmentation of hardware, including suture anchors.
Competed enrollment for US pilot clinical study of Cingal, a combination hyaluronic acid (HA) and fast-acting steroid injection for osteoarthritis knee pain.
Hosted an Investor Day, which detailed Anika’s multi-year strategy and roadmap of becoming a global leader in joint preservation and restoration.
Anika acquired Arthrosurface, a leading, privately-held provider of joint preservation solutions, and Parcus Medical, a leading, privately-held sports medicine company.
Cheryl R. Blanchard, Ph.D., appointed as President and Chief Executive Officer.
FDA 510(k) clearance received for its WristMotion Total Wrist Arthroplasty (TWA) System.
FDA 501(k) clearance received for Actiflip, a button fixation system for biceps tenodesis.
Tactoset was launched in the United States, a surgically delivered therapy for insufficiency fractures.
510(k) clearance received for the company’s first suture anchors comprised of biocomposite material bTCP/PLGA2.
FDA clearance received for Synd-EZ Kits for ankle syndesmosis repair2.
International launch of Cingal, the first HA-based viscosupplement plus steroid combination product for the treatment of osteoarthritis pain.
510(k) clearance received for the GFS Ultimate adjustable suture loop, further expanding the portfolio of graft fixation system (GFS) products2.
First surgery performed using the company’s first tissue-based product, the Glenojet® Allograft System for shoulder glenoid reconstruction1.
CE Mark approval received for Orthovisc®-T, a treatment designed to relieve pain and restore function for patients with chronic tennis elbow.
FDA clearance received for Draw Tight, an innovative suture-based anchor for use in both large and small joint repairs2.
First surgery performed using the anatomic OVO® implant for the treatment of glenohumeral osteoarthritis (OA) 1.
Received CE mark certification and launched its first sports medicine soft tissue repair solutions in the European Union2.
Acquired technology used in Hyalofast, a one-step cartilage regeneration product, through the strategic acquisition of Fidia Advanced Biopolymers, a leading innovator in hyaluronic acid-based tissue engineered products, based in Abano Terme, Italy.
Hyalofast received CE mark approval and launched internationally.
Received 510(k) clearance for the first PEEK CF (carbon fiber reinforced polyetheretherketone) suture anchors and interference screws used in sports medicine2.
First surgery performed using the Arthrosurface Toe HemiCAP® DF, its third anatomic foot & ankle implant brought to market since entering the foot & ankle space in 20051.
First surgery performed using the anatomic PF Wave® knee implant1.
First 510(k) clearances received for titanium soft tissue fixation devices2.
CE mark approval received for Monovisc in Europe.
Parcus Medical, LLC was founded by partners with extensive orthopedic industry experience2.
Obtained FDA approval for and launched Orthovisc in the United States.
First international anatomic joint preservation implant surgeries performed in the knee and shoulder1.
First anatomic joint preservation implant surgeries performed in the shoulder in the United States1.
Established a marketing and distribution relationship with Johnson & Johnson to sell Orthovisc in the United States once approved by the FDA.
Arthrosurface was founded and incorporated1.
Received CE mark approval for and launched Orthovisc internationally, the company’s first HA-based viscosupplement used for the treatment of osteoarthritis pain.
Signed a distribution agreement with Boehringer Ingelheim Vetmedica for its HA-based equine osteoarthritis product, Hyvisc®, a partnership that has continued to this day.
Anika Therapeutics was incorporated as a spin-off of MedChem Products, Inc.
Signed an agreement with Johnson & Johnson to manufacture and supply its hyaluronic acid-based ophthalmic products, Amvisc® and Amvisc® Plus.
- Brought to Anika through the acquisition of Arthrosurface, Inc.
- Brought to Anika through the acquisition of Parcus Medical LLC